Preview Newsletter

Q1 J&J Earnings

Traditional Media

Johnson & Johnson Beats Expectations, Boosts Guidance
Apr 19, 2016 | Wall Street Journal
By Anne Steele

Johnson & Johnson raised its guidance for the year as the health-care giant beat earnings expectations in the first quarter despite foreign exchange rates dragging revenue growth.
J&J's Drug Sales Help Health Giant Beat Earnings Estimates
Apr 19, 2016 | Bloomberg
By Cynthia Koon

Johnson & Johnson reported earnings that beat analysts’ estimates on strong sales of pharmaceuticals, the company’s biggest division.
Johnson & Johnson's Slow-Motion Shift
Apr 19, 2016 | Bloomberg
By Max Nisen

Johnson & Johnson doesn't want to explode its way out of the conglomerate business by breaking up. But it has been scooting with increasing rapidity in one particular direction.Many of J&J's peers once depended on medical devices and/or consumer products as well as drugs. But after years of spinoffs and asset sales, they are predominantly pharma companies. Novartis, for example, gets 81.2 percent of its revenue from pharmaceuticals, including generics. Pfizer is at 92 percent. At GSK, which is more diversified, pharma alone is still nearly 60 percent of its business, and vaccines add another 15.3 percent. J&J, in contrast, gets a mere 46.8 percent of its revenue from pharma products. The company's approach is working at surface level. Its first-quarter earnings per share, announced Tuesday morning, beat analyst estimates.
Johnson & Johnson shares rise on higher Q1 results
Apr 19, 2016 | USA Today
By Kevin McCoy

Shares of Johnson & Johnson (JNJ) shares rose Tuesday after the U.S. pharmaceutical giant reported stronger sales, posted first-quarter results that topped Wall Street forecasts and raised its fiscal guidance.
Johnson & Johnson Rides Strong Prescription Sales in 1Q
Apr 19, 2016 | Associated Press
By Linda Johnson

Johnson & Johnson on Tuesday posted a 0.6 percent decline in first-quarter profit, but still beat Wall Street's expectations as strong sales of prescription drugs nearly offset a big hit from the strong dollar.
Reuters: J&J shares hit new high on strong drug sales, weaker dollar
Apr 19, 2016 | Reuters
By Ransdell Pierson

Johnson & Johnson , the maker of Band-Aids and Tylenol, reported higher-than-expected quarterly earnings on Tuesday and nudged up its 2016 sales and earnings forecasts.
J&J to relaunch baby brand as millennials go organic
Apr 19, 2016 | Financial Times
By David Crow and Lindsay Whipp

Johnson & Johnson is relaunching its baby care business because millennial mothers are ditching its storied talcum powders and shampoos in favour of more expensive organic alternatives, making it the latest power brand to fall prey to the changing tastes of younger consumers.
Venezuela still biting, but J&J lifts forecasts
Apr 19, 2016 | Financial Times

Rising drug sales helped Johnson & Johnson, the world’s largest healthcare company, offset the sting of a stronger dollar during the first three months of the year.
Johnson & Johnson (JNJ) Shares Climb After Q1 Earnings Beat Expectations
Apr 19, 2016 | International Business Times
By Elizabeth Whitman

Shares of Johnson & Johnson (JNJ) are moving higher Tuesday to $110.93 a share, on track to hit a record high, after the pharmaceutical and health and wellness company reported a rise in first-quarter sales and higher-than-expected earnings of $1.54 per share, with adjusted diluted earnings per share coming to $1.68 for the quarter.
Johnson & Johnson Shares Poised to Hit Record After Earnings
Apr 19, 2016 | Fortune
By Daniel Bentley

Johnson & Johnson JNJ 0.68% , the maker of Band-Aids and Tylenol, reported higher-than-expected quarterly earnings on Tuesday and nudged up its 2016 sales and earnings forecasts.
Johnson & Johnson’s Q1 sales tick up
Apr 19, 2016 | Mass Device
By Brad Perielli

Johnson & Johnson (NYSE:JNJ) posted a slight increase in 1st-quarter sales in the face of headwinds from the strong dollar and Venezuela’s devaluation of the bolivar, but still managed to top Wall Street’s earnings forecast.
Johnson & Johnson's stock gains after profit beat, raised outlook
Apr 19, 2016 | MarketWatch
By Timi Kilgore

Johnson & Johnson's stock JNJ, +0.68% was indicated up 1% in light premarket trade Tuesday, after the consumer products and drug company beat first-quarter profit expectations, and lifted its full-year outlook.
Pharmalot, Pharmalittle: Little company makes big bet on discarded Roche drug
Apr 19, 2016 | STAT

Hello, everyone, and nice to finally see you. We apologize for the delay, but we encountered various technical difficulties this morning — not to mention Boston traffic. But we are persevering, nonetheless. After all, a routine is a routine, yes? So here is an assortment of interesting items for your convenience. As always, we hope you have a successful day and, again, remind you that we gladly accept receipt of secret documents.
Johnson & Johnson (JNJ) Tops Q1 EPS by 2c; Updates FY16 Outlook
Apr 19, 2016 | Street Insider

Johnson & Johnson (NYSE: JNJ) reported Q1 EPS of $1.68, $0.02 better than the analyst estimate of $1.66. Revenue for the quarter came in at $17.5 billion versus the consensus estimate of $17.5 billion.
Johnson & Johnson, (NYSE:JNJ) Reports 2016 First-Quarter Results; NovaGold Resources, (NYSEMKT:NG) Showed Slight Positive Change
Apr 19, 2016 | Wall Street 24

On Monday, Shares of Johnson & Johnson (NYSE:JNJ) inclined 0.68% to $110.93. The stock attained the volume of 7,772,685 shares. Johnson & Johnson declared sales of $17.5 billion for the first quarter of 2016, a boost of 0.6% as contrast to the first quarter of 2015.
Johnson & Johnson raises annual earnings, sales guidance
Apr 19, 2016 | FirstWord Pharma
By Joe Barber

Johnson & Johnson said Tuesday alongside its first-quarter financial results that it expects earnings per share this year to be between $6.53 and $6.68, lifted from prior guidance of $6.43 to $6.58. In addition, annual sales are predicted to be in the range of $71.2 billion to $71.9 billion, increased from an earlier estimate of $70.8 billion to $71.5 billion.
Johnson & Johnson Raises Forecast on Weaker Dollar
Apr 19, 2016 | 24/7 Wall Street
By Ausick

Johnson & Johnson (NYSE: JNJ) reported first-quarter 2016 results before markets opened Tuesday. The health care giant reported quarterly adjusted diluted earnings per share (EPS) of $1.68 on revenue of $17.5 billion. In the same period a year ago, it reported EPS of $1.56 on revenue of $17.37 billion. First-quarter results also compare to the consensus estimates for EPS of $1.65 and $17.48 billion in revenue.
Cramer: This stock has 'mojo'
| CNBC
By Fred Imbert

Not all stocks do, but CNBC's Jim Cramer said Tuesday Johnson & Johnson has "mojo."
Jim Cramer -- J&J Turning Into Battleground Stock
Apr 19, 2016 | The Street
By By Bret Knewell

Shares of Johnson & Johnson (JNJ - Get Report) are up 2.5% Tuesday, after reporting what TheStreet's Jim Cramer considered "unbelievable" earnings.
Goldman Sachs Group Inc, Johnson & Johnson Beat EPS Estimates
Apr 19, 2016 | ValueWalk
By Michelle Jones

Goldman Sachs and Johnson & Johnson released their latest quarterly earnings reports before opening bell this morning. Johnson & Johnson posted adjusted earnings of $1.68 per share for the first quarter, compared to the consensus of $1.65 per share. The company’s revenue came in at $17.48 billion against the consensus at $17.49 billion.
J&J Earnings Beat Estimates; Guidance Raised As FX Headwinds Ease
Apr 19, 2016 | Investor’s Business Daily
By Amy Reeves

Medical giant Johnson & Johnson (JNJ) beat Q1 estimates and raised guidance Tuesday morning, sending its stock to its fifth recent record high.
J&J's Imbruvica, Invokana fuel Street-beating Q1 sales
Apr 19, 2016 | FiercePharma
By Emily Wasserman

Johnson & Johnson’s ($JNJ) new products delivered again in Q1 2016, helping generate revenues that beat the Street’s estimates even as hep C sales lagged during the quarter.
J&J raises FY outlook, Q1 beats estimates
Apr 20, 2016 | Pharmafile
By Anjali Shukla

The company now sees full year earnings of $6.53 to $6.68 a share, up from $6.43 to $6.58 a share forecast earlier. J&J also raised its full year revenue estimates to $71.2 billion to $71.9 billion, from the previously estimated $70.8 billion to $71.5 billion
Stocks rise as S&P 500 tops 2100 for first time since December NYSE Post
Apr 20, 2016 | NYSE Post

This year it's also all about the guidance", she said. In recent trading, the Nasdaq has pulled back more firmly into negative territory and is now down 28.45 points or 0.6% at 4,931.56. First-quarter earnings at S&P 500 companies are expected to fall 7.7 percent on average, according to Thomson Reuters I/B/E/S.
Johnson & Johnson (JNJ) Climbed To A New High On Q1 Profit & Guidance Boost
Apr 20, 2016 | RTT News

Johnson & Johnson (JNJ) reported first quarter adjusted EPS of $1.68 Tuesday morning, compared to $1.56 a year ago. The consensus estimate was for EPS of $1.65.

Broadcast Media

Bloomberg GO Interview with Dominic Caruso
Apr 19, 2016 | Bloomberg GO

View Clip Here: http://app.criticalmention.com/app/#clip/view/22279397?token=e84d1d29-708f-4477-ac09-7e0d2b7f8222 (4:22)
CNBC Squawk Box Dominic Caruso Interview
Apr 19, 2016 | CNBC Squawk Box

View Clip Here: http://app.criticalmention.com/app/#clip/view/22279367?token=e84d1d29-708f-4477-ac09-7e0d2b7f8222 (4:52)
Bloomberg GO Video Clip
Apr 19, 2016 | Bloomberg GO

View Clip Here: http://app.criticalmention.com/app/#clip/view/22279381?token=e84d1d29-708f-4477-ac09-7e0d2b7f8222 (00:18)
CNBC Squawk Box Video Clip
Apr 19, 2016 | CNBC

View Clip Here: http://app.criticalmention.com/app/#clip/view/22279433?token=e84d1d29-708f-4477-ac09-7e0d2b7f8222 (00:30)
CNN Money With Maggie Lake Video Clip
Apr 19, 2016 | CNN

View Clip Here: http://app.criticalmention.com/app/#clip/view/22280374?token=e84d1d29-708f-4477-ac09-7e0d2b7f8222 (00:49)
CNBC Squawk on the Street, Jim Cramer on J&J Video Clip
Apr 19, 2016 | CNBC

CNBC Squawk on the Street, Jim Cramer on J&J View Clip Here: http://app.criticalmention.com/app/#clip/view/22280998?token=e32f4dc8-6f03-4a15-a1e5-868965281672 (00:21)
CNBC Squawk on the Street, Jim Cramer on J&J Video Clip
Apr 19, 2016 | CNBC

CNBC Squawk on the Street, Jim Cramer on J&J View Clip Here: http://app.criticalmention.com/app/#clip/view/22281137?token=e84d1d29-708f-4477-ac09-7e0d2b7f8222 (2:04 minutes)
Time Warner Cable News Video Clip
Apr 19, 2016 | TWC

View Clip Here: http://app.criticalmention.com/app/#clip/view/22284911?token=e84d1d29-708f-4477-ac09-7e0d2b7f8222 (00:28)
NBR (PBS) Video Clip
Apr 20, 2016 | PBS

View Clip Here: http://app.criticalmention.com/app/#clip/view/22288644?token=b65e9096-df32-4b3f-97e8-951884872d45 (00:49)
News 12 New Jersey Video Clip
Apr 20, 2016 | News 12 News Jersey

View Clip Here: http://app.criticalmention.com/app/#clip/view/22288633?token=b65e9096-df32-4b3f-97e8-951884872d45 (00:33)

Traditional Media

Johnson & Johnson Beats Expectations, Boosts Guidance

Apr 19, 2016 | Wall Street Journal

By Anne Steele

Johnson & Johnson raised its guidance for the year as the health-care giant beat earnings expectations in the first quarter despite foreign exchange rates dragging revenue growth.
The company now expects earnings for the year of $6.53 to $6.68 a share, up from previous guidance for $6.43 to $6.58 a share. J&J anticipates revenue of $71.2 billion to $71.9 billion, compared with previous guidance for $70.8 billion to $71.5 billion.
Chief Executive Alex Gorsky said the strong start to the year was supported by underlying sales growth.
“Our pharmaceuticals business continues to deliver impressive levels of growth, we have steady improvement in our consumer business, and we are seeing momentum in our medical-devices businesses, all of which are fueling our optimism for the full year ahead,” Mr. Gorsky said.
In January, J&J announced plans to cut about 3,000 jobs in its medical-devices division, or about 2.5% of the company’s total workforce, the company’s latest step to revive the struggling business.
The business used to be J&J’s largest, but it has stumbled amid pricing pressures, increased competition and market changes. In response, J&J has exited certain business, rejiggered how it sells devices and focused on high-growth categories like robotics and staplers.
In the first quarter, J&J’s medical device sales fell 2.4% to $6.11 billion, which represents about 35% of the company’s revenue.
Earnings in the first quarter fell to $4.29 billion, or $1.54 a share, from $4.32 billion, or $1.53 a share, in the same period last year. Excluding certain items, J&J had earnings of $1.68 a share in the latest quarter. Revenue edged up 0.6% to $17.48 billion. Unfavorable currency rates shaved 3.3% off the latest quarter’s total. Analysts had projected earnings of $1.65 a share on $17.48 billion in revenue, according to Thomson Reuters.
With about half of its sales overseas, J&J’s results have been pressured lately by a strengthening U.S. dollar and weakness in some emerging markets.
J&J’s pharmaceutical business, the company’s largest, grew 5.9% to $8.18 billion, lifted by a 12.9% increase in U.S. pharmaceutical sales. Strong sales of the diabetes drug Invokana, blood-cancer drug Imbruvica, blood-thinner Xarelto and multiple myeloma drug Darzalex, offset lower sales of the hepatitis drug Olysio, which is facing increased competition.
Shares of J&J, added 1.4% in light premarket trading to $112.50 after rising 14% over the past three months.

Return to headline | Return to top
J&J's Drug Sales Help Health Giant Beat Earnings Estimates

Apr 19, 2016 | Bloomberg

By Cynthia Koon

Johnson & Johnson reported earnings that beat analysts’ estimates on strong sales of pharmaceuticals, the company’s biggest division.
Drugs including Stelara, a psoriasis drug, and Xarelto, a blood thinner, were among the company’s major drug products that surpassed analysts’ expectations. Pharmaceutical sales have surpassed medical devices and consumer health products to become New Brunswick, New Jersey-based J&J’s biggest division.

Earnings, excluding one-time items, were $1.68 a share, beating the $1.65 average of 20 analysts’ estimates compiled by Bloomberg. The company raised its 2016 sales and earnings forecast, saying that foreign exchange rates would increase sales.
First-quarter sales grew less than 1 percent to $17.48 billion, compared with analysts’ expectations for $17.49 billion. Net income fell to $4.29 billion, or $1.54 a share, from $4.32 billion, or $1.53 a share, a year ago. For 2016, sales will be $71.2 billion to $71.9 billion. In January, the company projected sales of $70.8 billion to $71.5 billion. Earnings per share will be $6.53 to $6.68 a share, compared with the company’s past projection of $6.43 to $6.58.
The company’s shares rose 1.6 percent to $112.75 at 7:05 a.m. in New York trading before the market opened.
J&J may face competition for its biggest drug, arthritis treatment Remicade, after the U.S. Food and Drug Administration this month approved a cheaper, near-copy known as a biosimilar. Rival Pfizer Inc. could launch a competitor product as early as October, according to RBC analysts.
Meanwhile, J&J has started trimming its medical devices unit, its second-biggest division by sales. In January, the company said it planned to cut about 3,000 jobs from the business, or 4 to 6 percent of positions, during the next two years.
Here’s how each unit performed: Medical device sales fell 2.4 percent to $6.1 billion, though would have increased 0.5 percent without the negative effects of foreign exchange rates. Consumer product sales fell 5.8 percent to $3.2 billion, including a 5.6 percentage point negative impact from exchange rates. Pharmaceutical sales rose 5.9 percent to $8.2 billion, including a 2.6 percentage point negative impact from exchange rates

Return to headline | Return to top
Johnson & Johnson's Slow-Motion Shift

Apr 19, 2016 | Bloomberg

By Max Nisen

Johnson & Johnson doesn't want to explode its way out of the conglomerate business by breaking up. But it has been scooting with increasing rapidity in one particular direction.Many of J&J's peers once depended on medical devices and/or consumer products as well as drugs. But after years of spinoffs and asset sales, they are predominantly pharma companies. Novartis, for example, gets 81.2 percent of its revenue from pharmaceuticals, including generics. Pfizer is at 92 percent. At GSK, which is more diversified, pharma alone is still nearly 60 percent of its business, and vaccines add another 15.3 percent. J&J, in contrast, gets a mere 46.8 percent of its revenue from pharma products. The company's approach is working at surface level. Its first-quarter earnings per share, announced Tuesday morning, beat analyst estimates.
The company's shares opened at an all-time high on Tuesday and have beaten the rest of the sector so far this year.
LEADER OF THE PACK
But J&J's outperformance has nothing to do with the diversity of its business. It's all about the drugs. Pharma sales grew 8.2 percent compared to the same quarter last year. Consumer and device sales fell 5.8 and 2.4 percent, respectively.Three years ago, devices still outstripped pharma as a percentage of J&J's sales. Now pharma looks to be inching ever closer to an operationally meaningless, but psychologically significant, 50 percent of sales from 39.7 percent at the end of 2013. Investors are watching what the company will do with its $40 billion in cash and marketable securities. The company could try to regain revenue balance by buying more devices or consumer products. But the better bet is to focus on what's working, by bolstering its drug offerings even more.
Pharma's prominence at J&J is already likely to grow, even without acquisitions. Drugs such as psoriasis treatment Stelara, blood-cancer treatment Imbruvica , and blood thinner Xarelto beat analyst sales expectations in the latest quarter and are projected to keep growing. Stelara sales grew 33.9 percent in the quarter, while Imbruvica's more than doubled, and Xarelto grew by 28.6 percent. Analyst consensus estimates have the trio bringing in more than $6 billion in 2016.
J&J has a promising pipeline, as well. Last May, it told analysts it expected to launch 10 new products between 2015 and 2019 that have billion-dollar sales potential; the company reiterated that forecast on Tuesday. The big question mark is the company's best-selling drug Remicade, which brought in $6.5 billion in revenue last year. Just as the company likely feared, the FDA earlier this month approved a biosimilar copy of Remicade from Pfizer and Celltrion. Those firms may attempt to launch their version of the drug this fall. J&J has patents that last until 2018 and beyond and will fight the launch. It doesn't include biosimilar competition in the U.S. in its 2016 guidance. But that competition is coming, sooner or later. As a result of that looming threat and other potential competition, and because it's sitting on by far the biggest cash pile in the industry, there's major speculation the firm will buy up biotechs.
The company at least pointed in that direction on Tuesday's call. Speaking about how J&J might use its cash, CFO Dominic Caruso noted biotech valuations are coming down, while medical-device valuations remain "inflated." The company is cutting jobs in its devices business, which is being restructured. The division's last quarter of reported sales growth was in 2014. Its consumer division has been rocked by a series of quality control scandals, and J&J has relaunched a variety of its products as a result. The company's U.S. market share in pediatric over-the-counter products was about 70 percent before those issues; it's now 46 percent, according to the earning's call.
J&J reaffirmed its commitment to diversification on the call, with Caruso saying that having three major franchises lets it pursue opportunities in a changing health-care market "no matter where they be."
But money talks, and opportunity seems rather concentrated on the pharmaceutical side right now. Even if J&J resists calls from some shareholders to break up, the natural progression of its business is already making it more like its more pharma-centric peers. And that's just fine.

Return to headline | Return to top
Johnson & Johnson shares rise on higher Q1 results

Apr 19, 2016 | USA Today

By Kevin McCoy

Shares of Johnson & Johnson (JNJ) shares rose Tuesday after the U.S. pharmaceutical giant reported stronger sales, posted first-quarter results that topped Wall Street forecasts and raised its fiscal guidance.
However, the New Brunswick, N.J.-based company said its results were affected by a negative worldwide currency impact of 6.6%, as well as by Venezuela's currency devaluation.
Johnson & Johnson stock was was up 0.81% to $111.83 a share before U.S. financial markets opened.
The company's adjusted diluted earnings per share for the quarter came in at $1.68 billion, above the $1.65 consensus forecast of analysts surveyed by S&P Global Market Intelligence. Johnson & Johnson said its quarterly revenues were $17.48 billion, nearly matching the $17.491 billion prediction of Wall Street analysts.
Net income dipped to $4.29 billion, or $1.54 a share, down from $4.32 billion, or $1.53 a share, for last year's first quarter, the company reported.
Johnson & Johnson raised its sales guidance for the full year to $71.2 billion to $71.9 billion, reflecting expectations of improved foreign currency exchange rates. The company had predicted full-year sales of $70.8 billion to $71.5 billion three months ago.
Similarly, the firm increased its adjusted full-year earnings guidance to $6.53-$6.68 a share, up from earlier forecasts of $6.43 to $6.58 a share.
The forecasts assume that an equivalent and less expensive competitor for Remicade, the company's key arthritis medication Remicade, won't hit the market this year, Johnson & Johnson CFO Dominic Caruso told Bloomberg Go. However, the U.S. Food and Drug Administration approved Inflectra, a rival medication for Remicade, on April 5.
Johnson & Johnson said its worldwide operational sales growth was driven in part by new products, including Imbruvica, an oral therapy cancer medication approved for treating some B-cell malignancies, and Darzalex, a drug used to treat patients suffering from multiple myeloma, a blood cell cancer.
But the company also reported lower sales of Olysio, its hepatitis C medication, as rival treatments competed to treat patients.
The results were announced amid Johnson & Johnson move to cut costs in its medical devices business. In January, the company said it would eliminate approximately 3,000 of the division's jobs, affecting 4% to 6% of the head count in medical devices.
Worldwide medical devices sales for the first quarter dropped 2.4% from the same period last year to $6.1 billion, the company said.

Return to headline | Return to top
Johnson & Johnson Rides Strong Prescription Sales in 1Q

Apr 19, 2016 | Associated Press

By Linda Johnson

Johnson & Johnson beat Wall Street's modest expectations despite a 0.6 percent decline in first-quarter profit, as higher sales of new prescription drugs and other key medicines nearly offset a big hit from the strong dollar.
The world's biggest maker of health care products on Tuesday reported net income of $4.29 billion, or $1.54 per share, down from $4.32 billion, or $1.53 per share, in 2015's first quarter.
The maker of Band-Aids, prescription medicines and medical devices reported adjusted profit, which excluded amortization and restructuring costs, of $1.68 per share. That easily beat the average estimate of analysts for earnings of $1.64 per share.
Restrained production costs and lower sales, marketing and administrative expenses largely drove the earnings beat, Credit-Suisse analyst Vamil Divan wrote to investors.
The New Brunswick, New Jersey, company had revenue of $17.48 billion in the period, up 0.6 percent from the year-ago quarter, which topped Street forecasts for $17.42 billion.
Revenue was pulled down 3.3 percent by the strong dollar, which reduced the value of products bought in local currencies. Nearly half the company's sales are made overseas.
Like other multinational drug and device makers, J&J has been squeezed by unfavorable currency exchange rates for a couple years. However, the 3.3 percent hit is barely half of the 7 percent impact in the first quarter of 2015, Chief Financial Officer Dominic Caruso said.
That was one reason for J&J raising its 2016 profit forecast by a dime, to a range of $6.53 to $6.68 per share, from its January forecast. It also hiked its revenue forecast to a range of $71.2 billion to $71.9 billion, up from $70.8 billion to $71.5 billion.
Shares rose slightly before the opening bell.
"We carried last year's momentum into 2016," Caruso said, adding, "Underlying (sales) growth was a very strong 7 percent," after excluding the impact of various acquisitions and divestitures and the 86 percent plunge in sales of hepatitis C drug Olysio, to just $32 million in the first quarter.
That once-lucrative drug is being hammered by newer, more effective rival medicines such as Gilead Sciences Inc.'s Harvoni, which is raking in billions in sales every quarter.
"We're off to a strong start to the year, supported by our first-quarter underlying sales growth," CEO Alex Gorsky said in a company release. "Our Pharmaceuticals business continues to deliver impressive levels of growth, we have steady improvement in our Consumer business, and we are seeing momentum in our Medical Devices businesses, all of which are fueling our optimism for the full-year ahead."
The company began a restructuring of the medical devices and diagnostics unit earlier this year.
Sales of prescription drugs, J&J's biggest unit, jumped 5.9 percent to $8.18 billion, driven by higher sales of immune disorder drugs Remicade, Simponi and Stelara, and Xarelto for preventing heart attacks and strokes, plus sales of new blood cancer drug Imbruvica.
Sales of medical devices dipped 2.4 percent, to $6.11 billion. Meanwhile, sales of consumer health products such as pain reliever Tylenol fell 5.8 percent to $3.2 billion. Even excluding the effects of exchange rates, four of the six product categories — baby products, women's health, skinin care and wound care — still posted lower sales.
Caruso noted that sales of baby care items, which include Johnson's Baby Powder and No More Tears shampoo, were hurt by competition.
"It looks like millennial moms are trying a lot of organic, natural and what we call premium brands in that space," Caruso told journalists, adding that J&J plans a new marketing campaign for the baby business later this year.

Return to headline | Return to top
Reuters: J&J shares hit new high on strong drug sales, weaker dollar

Apr 19, 2016 | Reuters

By Ransdell Pierson

Johnson & Johnson (JNJ.N) beat quarterly earnings forecasts on strong prescription drug revenue and a weakening dollar, and it reassured investors that it did not expect its blockbuster Remicade arthritis drug to face U.S. competition this year.
The company also said on Tuesday that it remained on track to boost profit margins significantly this year, in part from cost cuts.
In a possibly encouraging signal for other drugmakers that will be reporting results in coming weeks, J&J said the strong dollar took a 3.3 percent bite out of global sales in the first quarter - half the impact in the prior period - as the currency's value eased somewhat.
J&J shares rose as much as 2.7 percent to an all-time high of $113.95. The ARCA Pharmaceutical Index .DRG of large drugmakers was up 0.6 percent, outpacing slight gains for the broad stock market.
Until this year, J&J shares had underperformed the healthcare sector every year since 2009 as the company grappled with patent expirations on important drugs and a slew of product recalls and manufacturing setbacks for its consumer division.
But J&J has recently introduced a number of fast-growing medicines. Pharmaceutical sales rose 5.9 percent to $8.2 billion in the first quarter, with increased demand for the Imbruvica cancer drug and Invokana diabetes treatment.
Sales of Remicade, J&J's biggest product, jumped 11.2 percent to $1.78 billion. But investors have been concerned it could be hurt by Inflectra, a cheaper version developed by South Korea's Celltrion Inc (068270.KQ) in partnership with Pfizer Inc (PFE.N). U.S. regulators approved Inflectra earlier this month, but a continuing patent battle between J&J and Celltrion has delayed its introduction.
J&J Chief Financial Officer Dominic Caruso said on Tuesday that strong patents should shield Remicade from biosimilar competition in 2016 and potentially for years to come.
The company is upgrading plants that make its consumer medicines, including Tylenol, to address longstanding quality control problems.
J&J is also restructuring its struggling medical device business to focus on areas like artificial knees and devices for trauma surgery.
Medical device sales slipped 2.4 percent to $6.1 billion in the quarter, while sales of consumer products fell 5.8 percent to $3.2 billion.
Total sales rose 0.6 percent to $17.48 billion, matching the analysts' average estimate compiled by Thomson Reuters I/B/E/S.
Net earnings fell to $4.29 billion, or $1.54 per share, from $4.32 billion, or $1.53 per share, a year earlier.
Excluding special items, J&J earned $1.68 per share, topping Wall Street expectations of $1.65.
"Overall it was a pretty solid quarter, with J&J beating earnings estimates and delivering on sales," said Edward Jones analyst Ashtyn Evans.
J&J said that based on current exchange rates, it expected sales of $71.2 billion to $71.9 billion in 2016, up from its January forecast of $70.8 billion to $71.5 billion. It raised its earnings outlook to between $6.53 and $6.68 a share from a prior range of $6.43 to $6.58.

Return to headline | Return to top
J&J to relaunch baby brand as millennials go organic

Apr 19, 2016 | Financial Times

By David Crow and Lindsay Whipp

Johnson & Johnson is relaunching its baby care business because millennial mothers are ditching its storied talcum powders and shampoos in favour of more expensive organic alternatives, making it the latest power brand to fall prey to the changing tastes of younger consumers.
US sales of J&J’s baby care products, including its “no more tears” shampoo and bedtime lotion, fell by 14 per cent year-on-year in the first quarter to $95m, their lowest level in a decade, after parents switched to all-natural products that are often made by much smaller companies.
Dominic Caruso, J&J’s chief financial officer, attributed the decline to “new competition, primarily from premium, natural-type brands”.
“It looks like millennial moms are buying new organic products,” he added.
Mr Caruso said the company had “robust plans to relaunch baby” this year and would provide further details next month. He said the group was open to buying competing products, but that it would focus “primarily on an internal remake”.
In February, the company was ordered by a state jury in Missouri to pay $72m in damages to the family of a woman whose death from ovarian cancer was linked to several decades of use of the company’s baby powder and another of its talc-based products.
J&J, which plans to appeal against the verdict, said there was no link between the publicity surrounding the case and falling sales of its baby products. “We don’t see any impact associated with that matter,” said Mr Caruso.
The company’s infant brands have been a mainstay for many parents ever since the launch of its Johnson’s baby powder in 1893, but more recently the group has struggled to combat the perception that some of its products contain dangerous chemicals.
In 2014, it agreed to remove two potentially harmful ingredients, formaldehyde and 1,4-dioxane, from its baby products, following pressure from consumers and environmental campaigners.
J&J announced the shake-up of its baby unit as it reported higher-than-expected earnings for the first quarter and nudged up its sales and profits forecasts for the full year, sending shares in the company up by 0.3 per cent in premarket trading to $111.25.
First-quarter sales rose 0.6 per cent to $17.48bn, led by demand for pharmaceuticals products in the US. However, overseas sales were hurt by a strong dollar and the devaluation of Venezuela's currency.
The company posted adjusted earnings per share of $1.68, two cents higher than the $1.65 that Wall Street analysts were typically expecting.
Based on current exchange rates, the company now expects sales of between $71.2bn and $71.9bn this year, up from its January estimate of $70.8bn to $71.5bn. It now expects full-year adjusted earnings per share in the range of $6.53-$6.68, up from its prior forecast of $6.43-$6.

Return to headline | Return to top
Venezuela still biting, but J&J lifts forecasts

Apr 19, 2016 | Financial Times

Rising drug sales helped Johnson & Johnson, the world’s largest healthcare company, offset the sting of a stronger dollar during the first three months of the year.
The company reported a rise in first quarter sales and lifted its full year sales and adjusted earnings guidance for this year as sales of key drugs – including its blockbuster inflammation treatment Remicade and Sterlara, a psoriasis drug – continue to deliver double digit growth.
Sales came in at $17.5bn, a 0.6 per cent rise from the prior year period and in line with expectations. Net earnings dipped 0.6 per cent to $4.3bn after it took a hit from Venezuela’s currency devaluation. Excluding that, adjusted earnings rose 6.1 per cent to $4.7bn, or $1.68 a share. Both were ahead of market forecast of $4.58bn, or $1.65 a share.
The New Jersey-based company spans three businesses: consumer products, pharmaceuticals and medical devices. And it is the pharmaceutical segment that continues to drive the company’s growth. Sales in the division rose 5.9 per cent to $8.1bn and the gains helped offset the declines seen in the other two divisions.
As a result, J&J bumped up its guidance for full year sales to $71.2bn-$71.9bn, compared to its previous forecast of $70.8bn-$71.5bn. Adjusted earnings guidance for the year was also lifted to $6.53-$6.68 per share from $6.43-$6.58 per share.

Shares in J&J jumped 1.4 per cent in pre-market trading.

Return to headline | Return to top
Johnson & Johnson (JNJ) Shares Climb After Q1 Earnings Beat Expectations

Apr 19, 2016 | International Business Times

By Elizabeth Whitman

Shares of Johnson & Johnson (JNJ) are moving higher Tuesday to $110.93 a share, on track to hit a record high, after the pharmaceutical and health and wellness company reported a rise in first-quarter sales and higher-than-expected earnings of $1.54 per share, with adjusted diluted earnings per share coming to $1.68 for the quarter.
Before the open, the company's stock rose more than 1 percent to $112.50, on track to for a record high.
Sales rose 0.6 percent to $17.48 billion the first quarter, the company announced Tuesday, reflecting a 7.2 increase in domestic sales but a 6 percent decrease in international sales. It said those numbers were affected by the strong dollar and the currency devaluation in Venezuela, with international sales hit with a negative currency impact of 6.6 percent. Net earnings fell to $4.29 billion the first quarter of this year, from $4.32 billion a year earlier.
Johnson & Johnson also readjusted its sales estimate for the year from $71.2 billion to $71.9 billion, up from the $70.8 billion to $71.5 billion it predicted in January. The New Jersey-based company also adjusted its expected earnings per share range for the year to $6.53 to $6.68 from the previously anticipated range of $6.43 to $6.58.
Those forecasts are based on the assumption that Remicade, Johnson & Johnson's arthritis medication, will not see competition hit the market this year, Dominic Caruso, the company's chief financial officer, told Bloomberg Go, even though the FDA earlier in April approved Inflectra, a similar drug.
"We are off to a strong start to the year, supported by our first quarter underlying sales growth," said Alex Gorsky, Johnson & Johnson's chairman and chief executive officer, in a statement.
Gorsky touted the Johnsons & Johnson's pharmaceuticals business, which makes Tylenol, as delivering "impressive levels of growth," and said the company was seeing "improvement" and "momentum" in its consumer and medical device sectors, respectively.
In its 2015 annual report, Johnson & Johnson said it expected to deliver “above-industry growth” in pharmaceuticals due to investment in research and development as well as “demonstrated record of disciplined acquisitions and licensing deals and strong in-market performance.” Last year, pharmaceuticals accounted for 45 percent of Johnson & Johnson's $70 billion in sales.

Return to headline | Return to top
Johnson & Johnson Shares Poised to Hit Record After Earnings

Apr 19, 2016 | Fortune

By Daniel Bentley

Johnson & Johnson JNJ 0.68% , the maker of Band-Aids and Tylenol, reported higher-than-expected quarterly earnings on Tuesday and nudged up its 2016 sales and earnings forecasts.
The company’s stock rose about 1.4 percent $112.50 in premarket trading, on track to open at a record high.
J&J’s first-quarter sales rose 0.6 percent to $17.48 billion, led by demand for pharmaceutical products in the United States. Overall, though, sales were constrained by the strong dollar and Venezuela’s currency devaluation.
Net earnings fell to $4.29 billion, or $1.54 per share, from $4.32 billion, or $1.53 per share, a year earlier.
Excluding special items, the company earned $1.68 per share, compared with the average analysts’ estimate of $1.65, according to Thomson Reuters I/B/E/S.
J&J said that based on current exchange rates, it now expected sales of $71.2 billion to $71.9 billion in 2016, up from its January forecast of $70.8 billion to $71.5 billion.
On an adjusted basis, it said it expected to earn $6.53-$6.68 per share for the year, up from its prior estimate of $6.43-$6.58.
The company’s pharmaceutical unit accounted for 45 percent of its $70 billion in sales last year. Medical devices made up for more than a third of sales, with over-the-counter medicines and other consumer products making up the rest.

Return to headline | Return to top
Johnson & Johnson’s Q1 sales tick up

Apr 19, 2016 | Mass Device

By Brad Perielli

Johnson & Johnson (NYSE:JNJ) posted a slight increase in 1st-quarter sales in the face of headwinds from the strong dollar and Venezuela’s devaluation of the bolivar, but still managed to top Wall Street’s earnings forecast.
Profits for the New Brunswick, N.J.-based healthcare titan were off by -0.6% at $4.29 billion, or $1.54 per share, on sales of $17.48 billion for the 3 months ended March 31. That’s a top-line gain of 0.6% compared with Q1 2015.
Adjusted to exclude 1-time items, earnings per share were $1.68, 3¢ ahead of The Street’s consensus forecast.
“We are off to a strong start to the year, supported by our 1st-quarter underlying sales growth,” chairman & CEO Alex Gorsky said in prepared remarks. “Our pharmaceuticals business continues to deliver impressive levels of growth, we have steady improvement in our consumer business, and we are seeing momentum in our medical devices businesses, all of which are fueling our optimism for the full year ahead.”
J&J also raised its outlook for the rest of 2016, saying it now expects to post adjusted EPS of $6.53 to $6.68 per share, up from $6.43 to $6.58. Sales are now expected to be $71.2 billion to $71.9 billion, compared with $70.8 billion to $71.5 billion previously.
Sales for Johnson & Johnson’s medical device business, the world’s largest, were off-6.5% overall at $6.11 billion, despite rising 2.2% to $3.03 billion in the U.S. International medical device sales were down -6.5% to $3.08 billion, the company said.
“Primary contributors to operational sales growth were electrophysiology products in the cardiovascular business; joint reconstruction products in the orthopaedics business; endocutters, energy and biosurgical products in the advanced surgery business; and international Acuvue contact lenses in the vision care business,” Johnson & Johnson said.

The company’s stock rose about 1.4% to $112.50 in pre-market trading, on track to open at a record high.

Return to headline | Return to top
Johnson & Johnson's stock gains after profit beat, raised outlook

Apr 19, 2016 | MarketWatch

By Timi Kilgore

Johnson & Johnson's stock JNJ, +0.68% was indicated up 1% in light premarket trade Tuesday, after the consumer products and drug company beat first-quarter profit expectations, and lifted its full-year outlook. Earnings for the latest quarter were $4.3 billion, or $1.54 a share, compared with $4.32 billion, or $1.53 a share, in the same period a year ago. Excluding non-recurring items, adjusted earnings per share came to $1.68, above the FactSet consensus of $1.65. Revenue rose 0.6% to $17.48 billion, just shy of the FactSet consensus of $17.49 billion, as 5.9% growth in pharmaceutical sales offset a 5.8% decline in consumer products and a 2.4% drop in medical devices. For 2016, company lifted its adjusted EPS outlook to $6.53 to $6.68 from $6.43 to $6.58 and revised its sales outlook to $71.2 billion to $71.9 billion from $70.8 billion to $71.5 billion. The stock has climbed 8% year to date through Monday, while the Dow Jones Industrial Average DJIA, +0.60% has gained 3.3%.

Return to headline | Return to top
Pharmalot, Pharmalittle: Little company makes big bet on discarded Roche drug

Apr 19, 2016 | STAT

Hello, everyone, and nice to finally see you. We apologize for the delay, but we encountered various technical difficulties this morning — not to mention Boston traffic. But we are persevering, nonetheless. After all, a routine is a routine, yes? So here is an assortment of interesting items for your convenience. As always, we hope you have a successful day and, again, remind you that we gladly accept receipt of secret documents.
DalCor Pharmaceuticals has raised $150 million in venture financing to start a 5,000-patient trial of a cholesterol drug that Roche shelved, the Wall Street Journal tells us. The big drug maker walked away from dalcetrapib after the pill failed to prevent heart attacks and strokes in a Phase 3 study. DalCor plans to analyze DNA of patients in the Roche study that revealed a variation in a single gene was associated with fewer heart attacks and strokes.
Novartis chief executive officer Joe Jimenez is battling to restore investor confidence in the drug maker after its stock has dropped more than a quarter in the past year, Swiss Info writes. Sales of its new heart drug have been disappointing, and its Alcon eye care business continues to struggle. Meanwhile, authorities in South Korea and Turkey are investigating its marketing practices.
CVS is working with Curbside, a mobile commerce firm, to offer store pickup at almost all of its nearly 8,000 stores by the end of this year, Fortune writes. The company, which is also taking an undisclosed stake in Curbside, is calling the service CVS Express. Pilot programs are underway in a few markets in California, North Carolina, and Georgia and set for a national rollout by year end.
Michael Pearson, the outgoing Valeant Pharmaceuticals chief executive officer, was deposed for at least nine hours Monday by a Senate committee investigating drug pricing practices, Bloomberg News reports.
Roche reported revenue in the first three months of this year rose 4 percent to $12.87 billion, which beat analyst forecasts and sets a pace that rival drug makers may find hard to match, Reuters says.
Johnson & Johnson beat Wall Street quarterly earnings forecasts and slightly boosted its outlook for 2016, citing strong prescription drug revenue and a weakening dollar, Reuters informs us.
Orexigen has again terminated a cardiovascular outcomes trial for its Contrave diet pill that was ordered by the US Food and Drug Administration, CardioBrief writes.
A federal judge ordered Warner Chilcott, which is now owned by Allergan, to pay $125 million to resolve criminal and civil claims in a health care fraud case, Reuters reports.

Return to headline | Return to top
Johnson & Johnson (JNJ) Tops Q1 EPS by 2c; Updates FY16 Outlook

Apr 19, 2016 | Street Insider

Johnson & Johnson (NYSE: JNJ) reported Q1 EPS of $1.68, $0.02 better than the analyst estimate of $1.66. Revenue for the quarter came in at $17.5 billion versus the consensus estimate of $17.5 billion.
Guidance:
Johnson & Johnson sees FY2016 EPS of $6.53 - $6.68, versus prior guidance of $6.43 - $6.58 and the consensus of $6.54. Johnson & Johnson sees FY2016 revenue of $71.2 - $71.9 billion, versus prior guidance of $70.8 - $71.5 billion and the consensus of $71.6 billion.
For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here

Return to headline | Return to top
Johnson & Johnson, (NYSE:JNJ) Reports 2016 First-Quarter Results; NovaGold Resources, (NYSEMKT:NG) Showed Slight Positive Change

Apr 19, 2016 | Wall Street 24

On Monday, Shares of Johnson & Johnson (NYSE:JNJ) inclined 0.68% to $110.93. The stock attained the volume of 7,772,685 shares. Johnson & Johnson declared sales of $17.5 billion for the first quarter of 2016, a boost of 0.6% as contrast to the first quarter of 2015. Operational sales results raised 3.9% and the negative impact of currency was 3.3%. Domestic sales raised 7.2%. International sales reduced 6.0%, reflecting operational growth of 0.6% and a negative currency impact of 6.6%. Apart From the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales raised 6.9%, domestic sales raised 9.8% and international sales raised 3.8%.* The currency devaluation in Venezuela negatively influenced worldwide operational sales growth by 60 basis points, and international sales growth by 120 basis points.
Net earnings and diluted earnings per share for the first quarter of 2016 were $4.3 billion and $1.54, respectively. First quarter 2016 net earnings included after-tax intangible amortization expense of about $0.2 billion and a charge for after-tax special items of about $0.2 billion. First quarter 2015 net earnings included after-tax intangible amortization expense of about $0.2 billion and a net gain for after-tax special items of about $0.1 billion. A reconciliation of non-GAAP financial measures is included as an accompanying plan. Apart From after-tax intangible amortization expense and special items, adjusted net earnings for the current quarter were $4.7 billion and adjusted diluted earnings per share were $1.68, representing increases of 6.1% and 7.7%, respectively, as contrast to the same period in 2015. On an operational basis, adjusted diluted earnings per share raised 10.3%.
Johnson & Johnson (NYSE:JNJ), as of current trade, has shown weekly upbeat performance of 1.80 percent which was maintained at 3.93 percent in 1-month period. The year-to-date (YTD) performance reflected a 8.78 percent above last year. During the past three months the stock gains 15.19 percent, bringing six-month performance to 15.86 percent. The stock holds the market capitalization of $306.48B.
Shares of NovaGold Resources Inc. (NYSEMKT:NG) inclined 0.17% to $5.99. NOVAGOLD RESOURCES INC. (NYSE MKT:NG) will hold the Company’s 2016 Annual Meeting of Shareholders on Friday, May 13 at 1:00 pm PT (4:00 pm ET) at Blake, Cassels & Graydon LLP (595 Burrard Street, Suite 2600, Three Bentall Centre, Vancouver, British Columbia).
For NovaGold Resources Inc. (NYSEMKT:NG), ATR value is at 0.28. If we take a look on its volatility, 3.44 percent was seen in a week and for the month it was 4.46 percent.

The stock is now trading at a distance of 10.76% from 20-day simple moving average. In the current trading session, the stock’s price moved 48.87% above its 200 day moving average. The stock is presently trading 17.71% above its SMA 50.

Return to headline | Return to top
Johnson & Johnson raises annual earnings, sales guidance

Apr 19, 2016 | FirstWord Pharma

By Joe Barber

Johnson & Johnson said Tuesday alongside its first-quarter financial results that it expects earnings per share this year to be between $6.53 and $6.68, lifted from prior guidance of $6.43 to $6.58. In addition, annual sales are predicted to be in the range of $71.2 billion to $71.9 billion, increased from an earlier estimate of $70.8 billion to $71.5 billion.
"We are off to a strong start to the year, supported by our first-quarter underlying sales growth," commented CEO Alex Gorsky, adding "our pharmaceuticals business continues to deliver impressive levels of growth." Sales of prescription drugs climbed 5.9 percent year-over-year to $8.2 billion, while overall revenue increased less than 1 percent to $17.5 billion, broadly in line with analyst estimates.

Net income for the three-month period was flat at $4.3 billion.

Return to headline | Return to top
Johnson & Johnson Raises Forecast on Weaker Dollar

Apr 19, 2016 | 24/7 Wall Street

By Ausick

Johnson & Johnson (NYSE: JNJ) reported first-quarter 2016 results before markets opened Tuesday. The health care giant reported quarterly adjusted diluted earnings per share (EPS) of $1.68 on revenue of $17.5 billion. In the same period a year ago, it reported EPS of $1.56 on revenue of $17.37 billion. First-quarter results also compare to the consensus estimates for EPS of $1.65 and $17.48 billion in revenue.
On a GAAP, basis the company posted EPS of $1.54, compared with $1.53 in the same period a year ago. Adjustments included after-tax intangible amortization expense of about $200 million and after-tax charge for special items totaling approximately the same amount.
Johnson & Johnson increased its adjusted earnings guidance for 2016 to a new range of $6.53 to $6.68 per share. Revenue guidance was raised to a range of $71.2 billion to $71.9 billion. The company said the new guidance reflects a weaker dollar which should prove a positive impact on revenues and earnings.
The consensus estimate called for full-year EPS of $6.54 on revenue of $71.55 billion. For the second quarter analysts are looking for $1.66 in EPS and revenue of $17.95 billion.
The firm’s CEO said:
Our Pharmaceuticals business continues to deliver impressive levels of growth, we have steady improvement in our Consumer business, and we are seeing momentum in our Medical Devices businesses, all of which are fueling our optimism for the full-year ahead.
Worldwide consumer sales declined by 5.8% year over year to $3.2 billion, including a negative currency impact of 5.6% and a negative operational impact of 0.2%. Pharmaceutical sales rose 5.9% to $8.2 billion on a jump of 12.9% in U.S. sales and a drop of 3.4% in international sales due to a negative currency impact of 6%. Medical devices sales fell 2.4% to $6.1 billion as a result of an operational increase of 0.5% and a negative currency impact of 2.9%.

Shares closed at $110.93 on Monday and were up 0.7% in Tuesday’s premarket trading to $111.83. The stock’s 52-week range is $81.79 to $111.10. The high was posted Monday. Thomson Reuters had a consensus analyst price target of about $111.53 before the results were announced. The dividend yield is 3.0%.

Return to headline | Return to top
Cramer: This stock has 'mojo'

| CNBC

By Fred Imbert

Not all stocks do, but CNBC's Jim Cramer said Tuesday Johnson & Johnson has "mojo."
"They came in jacked into the quarter, and they have mojo. I count 10 potential drugs of $1 billion in the pipe," Cramer said on "Squawk on the Street." "It's unbelievable."
Cramer made his remarks after the company reported better-than-expected earnings per share on revenues that were in line with expectations. The Dow component also raised its full-year guidance as it sees double-digit sales growth in the U.S.
Shares of Johnson & Johnson are up more than 9 percent year to date, and have gained 13 percent in the last 12 months. The stock also hit a new all-time intraday high of $113.95.

Return to headline | Return to top
Jim Cramer -- J&J Turning Into Battleground Stock

Apr 19, 2016 | The Street

By By Bret Knewell

Shares of Johnson & Johnson (JNJ - Get Report) are up 2.5% Tuesday, after reporting what TheStreet's Jim Cramer considered "unbelievable" earnings.
The company topped earnings per share estimates and missed slightly on revenue expectations. However, strong guidance are making investors very happy. Each of Johnson & Johnson's business segments was impressive, Cramer, the co-manager of the Action Alerts PLUS portfolio, said on CNBC's "Mad Dash" segment.
The health care product company's pipeline also looks attractive, with 10 potential drugs that could generate $1 billion or more in sales, he added.
However, this stock is starting to turn into a battleground because of its valuation. Right now, investors are warming up to cyclical and bank stocks, while others -- even if they're high-quality companies like J&J - are creating battles between bulls and bears.
"I think the stock should go higher," Cramer said. However, he asked, "If a guy is getting A's all the time and then he comes in with an A, do we pay a premium for that?"

Return to headline | Return to top
Goldman Sachs Group Inc, Johnson & Johnson Beat EPS Estimates

Apr 19, 2016 | ValueWalk

By Michelle Jones

Goldman Sachs and Johnson & Johnson released their latest quarterly earnings reports before opening bell this morning. Johnson & Johnson posted adjusted earnings of $1.68 per share for the first quarter, compared to the consensus of $1.65 per share. The company’s revenue came in at $17.48 billion against the consensus at $17.49 billion.
Goldman Sachs posted adjusted earnings of $2.68 per share, beating the consensus estimate of $2.42 per share. The firm came up short of revenue estimates, however, reporting $6.34 billion against the consensus of $6.73 billion.
Goldman Sachs said Investment Banking revenues tumbled 23% year over year to $1.46 billion, while Institutional Client Services revenue plummeted 37% to $3.44 billion. Investing and Lending revenue dropped precipitously to $87 million, while Investment Management revenue fell 15% to $1.35 billion.
“The operating environment this quarter presented a broad range of challenges, resulting in headwinds across virtually every one of our businesses,” Goldman Sachs Chairman and CEO Lloyd C. Blankfein said in a statement. “Looking ahead, we will continue to focus on delivering superior service to our clients and managing our business efficiently, which remain essential to generating shareholder value over the long term.”
Goldman Sachs shares fell by as much as 0.13% to $158.60 in premarket trading this morning.
Johnson & Johnson raises guidance
Johnson & Johnson’s reported earnings were $1.54 per share, compared to the year-ago quarter’s $1.53 per share. Operational sales climbed 3.9%, but the consumer products company said currency headwinds had a negative impact of 3.3%. Domestic sales rose 7.2%, while international sales declined 6% as the 6% negative impact from currencies more than offset the 0.6% increase in operational sales. Worldwide Consumer sales declined 5.8% year over year to $3.2 billion with the vast majority of that decline coming from currency exchange. Worldwide Pharmaceutical sales grew 5.9% to $8.2 billion
Management increased their guidance for sales this year to a range of $71.2 billion to $71.9 billion from the previous range of $70.8 billion to $71.5 billion. They also raised their full year adjusted earnings guidance to a range of $6.53 to $6.68 per share from the previous guidance of $6.43 to $6.58 per share.
Shares of Johnson & Johnson were inactive in premarket trading.

Return to headline | Return to top
J&J Earnings Beat Estimates; Guidance Raised As FX Headwinds Ease

Apr 19, 2016 | Investor’s Business Daily

By Amy Reeves

Medical giant Johnson & Johnson (JNJ) beat Q1 estimates and raised guidance Tuesday morning, sending its stock to its fifth recent record high.
J&J reported earnings of $1.68 a share, up 8% from the year-earlier quarter and beating analysts’ consensus by 3 cents, according to Thomson Reuters. Sales rose 0.6% to $17.48 billion, matching consensus. J&J said that the foreign-exchange impact knocked 6.6 percentage points off sales growth.
Nonetheless, the forex headwinds finally seem to be abating. J&J cited the improved forex outlook as the reason it was raising full-year sales guidance by $400 million, to $71.2 billion to $71.9 billion. It also added 10 cents to EPS guidance, now $6.53 to $6.68.
IBD’s Take: Johnson & Johnson rated No. 1 in its group, but CR is iffy.
“Our Pharmaceuticals business continues to deliver impressive levels of growth, we have steady improvement in our Consumer business, and we are seeing momentum in our Medical Devices businesses, all of which are fueling our optimism for the full-year ahead,” J&J CEO Alex Gorsky said in a statement.
J&J stock was up 2% in early trading on the stock market today, touching a record high of 113.60 intraday. The stock is up more than 10% for the year so far, and it is the first of three medical stocks that are hitting new highs and are reporting this week, the others being Intuitive Surgical (ISRG) this evening and Stryker (SYK) late Wednesday.
“This morning, J&J continued the growth momentum the company has seen in recent quarters, again delivering organic sales growth acceleration and its second consecutive quarter of double-digit EPS growth on an adjusted, operational basis,” wrote Leerink analyst Danielle Antalffy in a research note.
She noted that, excluding the impact of foreign exchange, M&A activity and shrinking sales of hepatitis C drug Olysio — which was made obsolete when Gilead Sciences (GILD) released Harvoni in late 2014 — sales rose 6.9%. Operating EPS growth was just above 10%.
Credit Suisse analyst Vamil Divan wrote that the pharma sales beat was driven by the immunology franchise — Remicade, Simponi and Stelara — as well as its stroke prevention treatment Xarelto.
But another top seller, diabetes drug Invokana, missed consensus by 19%. Investors had been wondering if Invokana would take a hit from Eli Lilly‘s (LLY) Jardiance, which last September proved that it could dramatically cut deaths from heart failure but didn’t get a sales bump from this in Q4.

Return to headline | Return to top
J&J's Imbruvica, Invokana fuel Street-beating Q1 sales

Apr 19, 2016 | FiercePharma

By Emily Wasserman

Johnson & Johnson’s ($JNJ) new products delivered again in Q1 2016, helping generate revenues that beat the Street’s estimates even as hep C sales lagged during the quarter.
The New Brunswick, NJ-based pharma giant posted sales of $17.5 billion, nearly matching analysts’ expectations of $17.48 billion. J&J can partly thank oncology drug Imbruvica for that haul. The drug’s worldwide sales shot up to $261 million from $116 million in Q4 2014. Diabetes med Invokana and combo Invokamet also delivered with $325 million in worldwide sales, a 17% increase.
These strong performances helped drive J&J to a Q1 win in pharma. Worldwide pharma sales came in at $8.2 billion in Q1, a 5.9% increase year-over-year.
Adjusted earnings also improved in Q1. The company’s adjusted earnings per share rang in at $1.68 billion, above the Street’s forecast of $1.65 billion.
Still, it didn’t all come up roses for J&J in Q1. Sales for hep C med Olysio plummeted to $32 million from $234 million in Q1 2015, an 86% drop, as the drug faces some stiff competition from Gilead ($GILD) and AbbVie’s ($ABBV) rival meds.
But despite the hep C miss, the company is “very pleased” with its “strong start for the year,” and sees big things in the months ahead, CFO Dominic Caruso said on J&J’s Q1 earnings call. The company’s pharma pipeline is “very, very robust” and includes new products with billion-dollar sales potential each, Caruso said.
And J&J isn’t too worried about biosimilar competition to Remicade, Caruso said. The company doesn’t expect any biosimilar rivals to take a bite out of sales this year, Caruso said, and J&J will defend patents on its bestseller that expire in 2018 and 2027.
The company is riding that optimism into the rest of 2016. J&J raised its full-year sales guidance to $71.2 billion to $71.9 billion, higher than the forecast of $70.8 billion to $71.5 billion that it set out three months ago. J&J also upped its adjusted full-year earnings guidance to $6.53-$6.68 a share, up from earlier forecasts of $6.43 to $6.58 a share.
It could be a difficult road ahead for J&J, especially after Pfizer ($PFE) and Allergan’s ($AGN) megamerger collapsed under new tax inversion rules. “It’s probably true” that the companies’ return to the market as individual entities creates more competition, Caruso said.
But J&J is “accustomed to looking at various acquisition candidates” and some deal valuations could still prove lucrative, Caruso said. “We’re patient, disciplined, and we’ll look for the right opportunity at the right time with the right valuation.”

Return to headline | Return to top
J&J raises FY outlook, Q1 beats estimates

Apr 20, 2016 | Pharmafile

By Anjali Shukla

The company now sees full year earnings of $6.53 to $6.68 a share, up from $6.43 to $6.58 a share forecast earlier. J&J also raised its full year revenue estimates to $71.2 billion to $71.9 billion, from the previously estimated $70.8 billion to $71.5 billion
Chief Executive Alex Gorsky said: “We are off to a strong start to the year, supported by our first quarter underlying sales growth. Our pharmaceuticals business continues to deliver impressive levels of growth, we have steady improvement in our consumer business, and we are seeing momentum in our medical devices businesses, all of which are fuelling our optimism for the full-year ahead.”
For the first quarter J&J reported earnings of $4.3 billion with sales of $17.5 billion. Adjusted earnings per share excluding special items stood at $1.68.
J&J’s pharmaceutical business grew 5.9% to $8.18 billion, driven by a 12.9% increase in US pharmaceutical sales. Sales of hepatitis C drug Olysio were impacted by new competition. However, the overall impact was offset by strong sales of the diabetes drug Invokana, blood-cancer drug Imbruvica, blood-thinner Xarelto and multiple myeloma drug Darzalex.
Worldwide medical devices sales at $6.1 billion represented a drop of 2.4% versus the prior year. Domestic sales increased 2.2% while international sales were down 6.5%.

Return to headline | Return to top
Stocks rise as S&P 500 tops 2100 for first time since December NYSE Post

Apr 20, 2016 | NYSE Post

"This year it's also all about the guidance", she said.
In recent trading, the Nasdaq has pulled back more firmly into negative territory and is now down 28.45 points or 0.6% at 4,931.56. First-quarter earnings at S&P 500 companies are expected to fall 7.7 percent on average, according to Thomson Reuters I/B/E/S.
April 19 The S&P 500 breached 2,100 on Tuesday, about 30 points shy of its record high, boosted by a rise in crude and earnings reports from heavyweights Goldman Sachs and Johnson & Johnson. MINE THIS: Several mining companies were up sharply.
The renewable energy company says that this Agreement means it can now start working with EMC to deliver its patented CETO wave energy technology as part of an integrated microgrid solution. The stock added $1.75 to $112.68.
FORECAST LETDOWN: Illumina sank 23.2 percent after the genetic testing tools maker predicted that sales in the first quarter will be far lower than analysts expected. The company also said it would cut back on participating in Affordable Care Act health care exchanges in a bid to stem losses related to the program.
Prime Media Group (ASX:PRT) has announced that its total advertising revenue in northern NSW, southern NSW and Victoria has dropped 7.4% for the financial year to 31 March, compared to the market decline of 6.8%.
Steel stocks also turned in a strong performance on the day, with the NYSE Arca Steel Index soaring by 4 percent to a nine-month closing high. The stock added $4.11 to $86.52. "It's very much about how companies expect to do for the next three quarters over the year".
Netflix shares fell 12 percent after the video streaming service's subscriber forecast missed estimates.
But Wall Street remains extremely cautious about first-quarter reports. The stock shed $8.40 to $144.07. Commodity shares also fell, including Australian mining giant BHP Billiton, which lost 3 percent. The Dow and the S&P 500 are holding on to modest gains, while the Nasdaq remains in the red.
OIL IMPACT: Chesapeake Energy slid 20 cents, or 3.3 per cent, to $5.83 as the price of crude declined. Energy was up 1.29 percent.
Williams Cos. was among the energy and drilling services companies to get a boost. The OPEC member pumped 2.8 million barrels in March, making it the fourth-largest producer in the 13-nation cartel headed by Saudi Arabia. Brent crude, the global benchmark, gained $1.12, or 2.6 percent, to close at $44.03 a barrel in London. Exporters Honda Motor Co. jumped 4.5 percent and Mazda Motor Corp. surged 7.2 percent.
It's a pretty sweet milestone considering the Dow plunged to just 15,451 in January, as Wall Street freaked out over the crash in oil prices and China's economic slowdown.
It's up 2.3 percent at 10,350.
Japan's Nikkei stock index ended up 3.7%, a day after it fell 3.4% as investors assessed the impact of earthquakes in southwestern Japan's Kyushu on manufacturers' supply chains. The contract fell 58 cents, or 1.4 percent, to close at $39.78 a barrel on Monday. Heating oil added 3 cents, or 2.2 percent, to close at $1.26 a gallon.

Return to headline | Return to top
Johnson & Johnson (JNJ) Climbed To A New High On Q1 Profit & Guidance Boost

Apr 20, 2016 | RTT News

Johnson & Johnson (JNJ) reported first quarter adjusted EPS of $1.68 Tuesday morning, compared to $1.56 a year ago. The consensus estimate was for EPS of $1.65.
The company also increased its full year adjusted EPS forecast to between $6.53 and $6.68, from prior expectations of $6.43 to $6.58. The consensus estimate is for EPS of $6.54.
Johnson & Johnson gapped up slightly Tuesday and rose sharply during the first half hour of trade. The stock closed up by 1.75 at $112.68. Johnson & Johnson has been on an upward trend for over 2 months and set its second consecutive new high for the year.

Return to headline | Return to top

Broadcast Media

Bloomberg GO Interview with Dominic Caruso

Apr 19, 2016 | Bloomberg GO

View Clip Here: http://app.criticalmention.com/app/#clip/view/22279397?token=e84d1d29-708f-4477-ac09-7e0d2b7f8222

(4:22)

Return to headline | Return to top
CNBC Squawk Box Dominic Caruso Interview

Apr 19, 2016 | CNBC Squawk Box

View Clip Here: http://app.criticalmention.com/app/#clip/view/22279367?token=e84d1d29-708f-4477-ac09-7e0d2b7f8222
(4:52)

Return to headline | Return to top
Bloomberg GO Video Clip

Apr 19, 2016 | Bloomberg GO

View Clip Here: http://app.criticalmention.com/app/#clip/view/22279381?token=e84d1d29-708f-4477-ac09-7e0d2b7f8222

(00:18)

Return to headline | Return to top
CNBC Squawk Box Video Clip

Apr 19, 2016 | CNBC

View Clip Here: http://app.criticalmention.com/app/#clip/view/22279433?token=e84d1d29-708f-4477-ac09-7e0d2b7f8222 (00:30)

Return to headline | Return to top
CNN Money With Maggie Lake Video Clip

Apr 19, 2016 | CNN

View Clip Here: http://app.criticalmention.com/app/#clip/view/22280374?token=e84d1d29-708f-4477-ac09-7e0d2b7f8222 (00:49)

Return to headline | Return to top
CNBC Squawk on the Street, Jim Cramer on J&J Video Clip

Apr 19, 2016 | CNBC

CNBC Squawk on the Street, Jim Cramer on J&J

View Clip Here: http://app.criticalmention.com/app/#clip/view/22280998?token=e32f4dc8-6f03-4a15-a1e5-868965281672 (00:21)

Return to headline | Return to top
CNBC Squawk on the Street, Jim Cramer on J&J Video Clip

Apr 19, 2016 | CNBC

CNBC Squawk on the Street, Jim Cramer on J&J
View Clip Here: http://app.criticalmention.com/app/#clip/view/22281137?token=e84d1d29-708f-4477-ac09-7e0d2b7f8222 (2:04 minutes)

Return to headline | Return to top
Time Warner Cable News Video Clip

Apr 19, 2016 | TWC

View Clip Here: http://app.criticalmention.com/app/#clip/view/22284911?token=e84d1d29-708f-4477-ac09-7e0d2b7f8222 (00:28)

Return to headline | Return to top
NBR (PBS) Video Clip

Apr 20, 2016 | PBS

View Clip Here: http://app.criticalmention.com/app/#clip/view/22288644?token=b65e9096-df32-4b3f-97e8-951884872d45 (00:49)

Return to headline | Return to top
News 12 New Jersey Video Clip

Apr 20, 2016 | News 12 News Jersey

View Clip Here: http://app.criticalmention.com/app/#clip/view/22288633?token=b65e9096-df32-4b3f-97e8-951884872d45 (00:33)

Return to headline | Return to top

Add recipients

Suggested